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ABSTRACT
The human leukocyte antigen (HLA) complex con-
tains the most polymorphic genes in the human
genome. The classical HLA class I and II genes de-
fine the specificity of adaptive immune responses.
Genetic variation at the HLA genes is associated
with susceptibility to autoimmune and infectious
diseases and plays a major role in transplantation
medicine and immunology. Currently, the HLA genes
are characterized using Sanger- or next-generation
sequencing (NGS) of a limited amplicon repertoire
or labeled oligonucleotides for allele-specific se-
quences. High-quality NGS-based methods are in
proprietary use and not publicly available. Here, we
introduce the first highly automated open-kit/open-
source HLA-typing method for NGS. The method
employs in-solution targeted capturing of the clas-
sical class I (HLA-A, HLA-B, HLA-C) and class
II HLA genes (HLA-DRB1, HLA-DQA1, HLA-DQB1,
HLA-DPA1, HLA-DPB1). The calling algorithm allows
for highly confident allele-calling to three-field reso-
lution (cDNA nucleotide variants). The method was
validated on 357 commercially available DNA sam-
ples with known HLA alleles obtained by classical
typing. Our results showed on average an accurate
allele call rate of 0.99 in a fully automated manner,
identifying also errors in the reference data. Finally,
our method provides the flexibility to add further en-
richment target regions.
INTRODUCTION
The human leukocyte antigen (HLA) complex is located on
chromosome 6p21 and comprises dozens of genes impor-
tant for immune function (1,2). Of key importance for deter-
mining the antigenic specificities of the adaptive immune re-
sponse, one gene family encoded in the HLA complex com-
prises the ‘classical’ HLA genes (3,4). Accurate assignment
of individualHLAalleles at these loci is essential within sev-
eral disciplines, e.g. clinical transplantation medicine (5,6),
inflammatory disease susceptibility research (7–9), tumor
immunology (10–12) and evolutionary biology (13).
Up to recently, HLA typing has mainly been carried
out using sequence-specific oligonucleotide probes (SSOP),
sequence-specific primers (SSP) and sequence-based typing
(SBT) using Sanger sequencing of exons 2 and 3 in class I
HLA genes (HLA-A/B/C) or exon 2 in class II HLA genes
(HLA-DR/DQ/DP). High-resolution (i.e. covering all cod-
ing variation and by nomenclature consensus at least the
first and second field, classically ‘four digits’) typing by
means of SSOP and/or SSP usually is an iterative approach
that starts with low-resolution typing (i.e. first field, classi-
cally two digits), followed by additional characterizations
to the extent needed by the application. This process is time
consuming and incompatible with any high-throughput re-
search context. Sanger sequencing-based typing has the ca-
pability to perform high-resolution typing, but demands
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polymerase chain reaction (PCR) amplification of individ-
ual exons at each locus and often several separate sequenc-
ing reactions for each amplicon. Moreover, the results usu-
ally contain a large number of cis/trans ambiguities, i.e.
heterozygous positions cannot be adequately phased and
all alleles matching the sequencing outcome are thus listed
as possible genotype combinations. A PCR and Sanger se-
quencing based method that generates unambiguous HLA
typing for four HLA loci was published by Voorter et al.
(14). Even though it is automatable and delivers reliable re-
sults, practical challenges of all PCR-based approaches re-
main.
In recent years alternative SBT methods using next-
generation sequencing (NGS) technology have emerged
(15–20). Most of these NGS methods rely on traditional
PCR of the target regions followed by massive parallel
sequencing of the amplicons. The advantage of NGS is
the single strand sequencing nature combined with the in-
creased amount of sequencing reads per sample and lo-
cus. This allows for a highly confident allele-determination,
hereafter referred to as calling. Because of the single-strand
derived NGS reads, the new typing approaches often allow
for intragenic phasing between polymorphic nucleotides.
However, the limitations of the initial PCR remain for these
NGS approaches. Amplicon-based methods are laborious,
require extensive PCR primer optimization steps and often
demand a manual curation of results.
For targeted NGS, array-based (21) and bead-based (22)
enrichment techniques are well established and widely used.
The advantages of these oligonucleotide-based enrichments
are their ease of use as no extra instrumentation and PCR
optimizations are necessary, plus the flexibility to enrich
genomic targets of different sizes and complexity. Today
whole-exome enrichments are widely used by NGS plat-
forms and different groups worldwide. Major et al. (23)
published an HLA in silico typing approach where whole
exome andwhole genomeNGSdata from the 1000 genomes
project was employed (24). As exemplified by this appli-
cation, traditional exome enrichment for HLA genotyping
may however result in allelic dropout, because the target
baits are designed based on the standard human reference
genome sequence not accounting for the allelic variation
at the HLA loci. The complexity of the classical HLA loci
challenges the development of specific diagnostic-grade en-
richment kits. Nevertheless, the collection of known HLA
allele sequences is large, captures probably all common
alleles and is publicly available (25). Here we present an
in-solution targeted enrichment approach for NGS-based
HLA genotyping without PCR-based amplification. Our
approach consists of a complete turnaround for HLA se-
quencing including a user-friendly software tool for assign-
ing HLA alleles.
MATERIALS AND METHODS
Selection of DNAs for benchmark study
Sample selectionwasmade computationally with the aim of
maximizing allelic diversity of the reference set. We started
with a collection of 892 cell lines, 584 from the Interna-
tional HistocompatibilityWorkingGroup (IHWG) and 308
from the EBRCC-Cell Culture Laboratory in Hannover,
Germany. For the complete sample set we ran 100,000 ran-
dom selections. For each of these selections we performed
the following process: one random sample was drawn with-
out putting it back. If a drawn sample had at least one al-
lele that was not drawn before, we put it into the pool of
reference samples. Otherwise it was discarded. New sam-
ples were drawn until all available reference alleles were in
the reference pool. After 100,000 of these runs the pool with
the smallest number of samples (n= 333) was selected (Sup-
plementary Table S1). During the ordering process it turned
out that 36 samples could not be provided. Therefore, addi-
tional samples (n = 60) from IHWG and the EBRCC-Cell
Culture Laboratory in Hannover were manually selected to
add diversity to the reduced reference set. The final sample
set including all NGS HLA-typing results is listed in Sup-
plementary Table S2.
Design of RNA baits for targeted enrichment
Commercially available targeted enrichment design nor-
mally allows the user to define the genes and genomic tar-
gets of interest. The capture probes (baits) are then designed
based on reference sequences. In pilot experiments (data not
shown) we tested such bait designs targeting only the HLA
alleles of the human genome reference sequence. Results
from this pilot showed poor concordance between NGS-
based and classically determined HLA alleles. This is likely
due to failed enrichment because of incomplete reference
data when designing the bait set. As expected, the HLA
allele enrichment success rate was 100% (data not shown)
when DNA from the homozygous HLA reference cell lines
were sequenced (26). We hypothesized––although the RNA
baits allow for a few mismatches in the hybridization re-
action (27)––that an improved bait design was needed to
capture the diverse and large number of known HLA alle-
les. Consequently, we designed an HLA bait panel based on
the complete collection of available IMGT/HLA reference
sequences. The resulting targeted enrichment showed com-
pleteness for our reference panel, at the expense of a loss of
evenness.
First a non-overlapping tiling of the hg19 MHC refer-
ence sequence was performed to design the RNAbaits. This
tiling included the chr6 MHC (haplotype pgf) plus addi-
tional sequences of the available haploid MHC sequences
of hg19, i.e. apd, cox, dbb,mann mou,mcf, qbl and ssto (26).
Next, all available cDNA and gDNA sequences were down-
loaded from the IMGT/HLA database version 3.09 (28).
In an iterative approach we started aligning all the designed
baits against the first gDNA (five mismatches allowed). If
an uncovered region with length greater or equal the bait
length could be identified, this sequence was tiled to retrieve
additional baits. For each gDNA sequence the aforemen-
tioned step was repeated. After this process was finished
the same procedure was performed on the cDNAcollection.
For the cDNA collection each exon was treated like a stand-
alone sequence. The complete bait design can be found in
the Supplementary Data.
Targeted enrichment, library preparation and sequencing
Targeted enrichment and sample preparation was done
with the Agilent R© SureSelectXT (http://www.chem.agilent.
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com) automation kits on a Bravo R© (http://www.chem.
agilent.com) liquid handling system. The SureSelectXT
kit provides library preparation and targeted enrich-
ment in one kit. The amount of input genomic DNA
used in our study was 3 g but more recent proto-
cols like the transposase-based SureSelectQXT (Agilent)
require 50 ng only. At our online resource (see QXT
folder of the sftp repository; http://www.ikmb.uni-kiel.
de/resources/download-tools/software/hlassign) we provide
example data for eight samples processed with the SureS-
electQXT protocol. The RNA bait length was 120 bp. Se-
quencing was performed on an IlluminaHiSeq2000 R© (http:
//systems.illumina.com) with 100 bp paired-end runs. For
the targeted enrichment we chose a fragment size between
150 and 300 base pairs and pooled 48 samples per lane. The
48 sample pools provided on average 5,044,060 paired reads
per sample (median 4,481,579). We observed an increased
error rate for the samples with less read count. So the calling
becomes more confident with the higher number of reads
obtained. It is difficult to determine an exact lower thresh-
old for high confidence, but taking Supplementary Figure
S1 into account we would suggest at least 7 million reads
(3.5 million paired reads) as a lower threshold.
Bioinformatic data analysis
All fastq reads of a sample were aligned against the cDNA
collection of the IMGT/HLA database. Importantly, we al-
lowed perfectmatches only. The only exception that allowed
for truncated alignments were alignments that start and/or
end at exon boundaries. Before calling started we reduced
the complexity of the data set by reducing the number of
mappings to single start point mappings. All cDNA align-
ments that were not completely covered were discarded. In
analogy to Wang et al. (20), we also calculated the cen-
tral read coverage for all cDNAs. If the relation of (cen-
tral reads)/(noncentral reads) dropped below 0.2 the cDNA
was discarded. Of the remaining sequences, all possible al-
lele combinations were analyzed. For both alleles of each
allele combination we calculated the coverage as area under
the curve (auc), the number of reads that map exclusive to
one of the both alleles (allele-specific mappings, asm), the
number of mapped pairs per read (mppr) and the length of
the mappable sequence (msl). The read equality (req) was
calculated as min(asm)/max(asm). After these values were
calculated for all allele combinations we scaled the values
between 0 and 1 [0;1.0]. The most likely genotype was the
one that had the highest harmonic mean for all these mea-
sures. Details about the parameter selection and weighting
are summarized in the Supplementary Methods. The call-
ing was performed at a Linux cluster (CentOS 5.8, Linux
version 2.6.18–308.13.1.el5) with one core per sample and
locus.
Weighted harmonic mean
H =
(∑5
k=1
1
Wk
)
∗∏5k=1 Pk(∑5
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1
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)
P: The parameters describing the read mapping. These pa-
rameters are described in detail above. w: The weighting of
the different parameters. P= {asm,req,msl,mppr,auc};w=
{0.5, 1, 0.1, 0.1, 1}
For these parameters the concrete formula is:
H = (2 + 1+ 10 + 10 + 1) ∗ asm ∗ req ∗msl ∗mppr ∗ auc
2 ∗ asm+ 1 ∗ req + 10 ∗msl + 10 ∗mppr + 1 ∗ auc
The data analysis that we performed consists of two main
steps. The first step is a filtering step, which reduces the num-
ber of possible alleles. In a second step the method tries to
determine the most likely genotype of the sample. To pass
filtering, an allele must have full coverage and in analogy to
Wang et al. (20) a specific central read coverage. This pre-
filtering performs best when the sample has high unique
start point coverage. For low coverage samples, the pre-
filtering step should be less stringent. So if a sample with
low coverage (auc < 0.5) is observed, it is recommended to
manually verify the alleles that are filtered out but have a
low error (upper right table of Figure 1). The aforedescribed
scenario is the main reason for an erroneous result of the
fully automated calling. By manual verifying the results in
the way described above, it is possible to assign the cor-
rect allele in all instances. In the Supplementary Methods
we describe how we estimated and verified the parameters
we chose for the genotype calling algorithm. The harmonic
mean function that we use weighs the parameters differ-
entially. For the parameters asm (weighted half), number
of mppr (weighted 0.1) and length of mappable sequence
(weighted 0.1), we tested the calling performance for full,
half and 0.1 weighted. With the here-in described weighting
we achieved the best results for our test set. The test set con-
sisted of 20 samples. For those samples we had classically
determined HLA types and HLA types from imputation
(29,30). These HLA types had a one-to-two field resolution
(Supplementary Methods Table 1). With this data set we
were not able to validate our results at a three-field resolu-
tion. Nevertheless, we proceeded with that data, determined
the above-described weights, for which we achieved an over-
all genotype concordance of 97% in a fully automated man-
ner, and ordered the validation sample set that we used in
this study. With the results of this study, we now present
an excellent reference set, representing a broad diversity of
HLA alleles. In a future study we will split the larger data
set into two parts and use one part for determining the op-
timal weights and the second part for validation. This opti-
mization will likely increase the accuracy of our automated
calling algorithm even further.
HLA-typing workflow
Day 1: Perform the DNA library preparation and start the
in-solution target capturing protocol until incubation of the
hybridization starts. Day 2: Completing the targeted enrich-
ment and pool up to 48 samples. Day 3: Load the sequenc-
ing machines and start sequencing. A MiSeq run may be
finished after 2 days, a HiSeq run after 10 days. Analysis
of the demultiplexed fastq files takes ∼5 min per sample on
four cores of an Ubuntu Linux PC with the GUI version.
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Figure 1. Analysis software. The figure shows a screenshot of the GUI (graphical user interface) of the analysis software. For this figure, we combined two
screenshots of two different data views, separated by the white diagonal line. The left part of the graph shows the achieved single start point coverage (see
also Figure 2 for further details). The right part shows the corresponding single start point mappings of the same alignment. The different parts of the
user interface are as follows: The list view on the left shows samples that are added for analysis. This sample list consists of the sample name followed by
a colored rectangle. The colors are coding for the sample states, which are white (added for analysis), yellow (analysis running), green (analysis finished)
and red (analysis failed). The middle part is divided into three sections. At the top, the user can select the locus for the selected sample. The ‘change
view’ button at the right switches between coverage and read view. Below, the user finds the NGS data visualization of the determined HLA type. The
table at the bottom shows a sorted list of the different possible HLA types. The top most HLA type is the most likely determined by the algorithm.
The user can change that order to manually correct possible errors. At the right side of the GUI the user finds two additional tables. The upper table
contains a sorted list of alleles that failed the initial QC (see Materials and Methods). The column ‘error’ shows the number of nucleotide positions,
for which a QC failed value was calculated. The lower table shows the top 50 alleles that were not covered 100%. The table is sorted by the number of
uncovered bases in ascending order. Alleles from these two tables can manually be included in the genotype calling. On the other hand, the user can
move alleles from the allele calling to one of these tables. This allows for manual evaluation of the calling algorithm. Low covered alleles that failed the
initial pre-filtering step can be added. Also degraded DNA, that is not 100% covered, can be analyzed. At the top of the application window, the user
finds a small gray bar. When the mouse pointer hovers this area, a toolbox with buttons for sample adding, starting analysis and analysis report moves
down (shown at the bottom, below the status bar). A tutorial that contains more details and an example workflow can be found at our online resource
http://www.ikmb.uni-kiel.de/resources/download-tools/software/hlassign.
Implementation and availability of tool
The analysis software is written in C/C++ code. The graph-
ical version of the software implements multithreading and
enables the user to verify the automated HLA calling re-
sults (Figure 1). It also has functionality to evaluate and
manipulate the calling results and save the results as a
comma-separated value (csv) file. It runs at a modern desk-
top computer but ismemory intensivewhen analyzingmany
samples in one step. For an analysis of 48 samples we
recommend 8GB RAM. Test data and the software can
be downloaded at http://www.ikmb.uni-kiel.de/resources/
download-tools/software/hlassign. The project described
here was performed with a console application on a Linux
cluster. The source code and a CentOS executable are pro-
vided. The console version utilizes a preinstalled Blat (31)
for the alignment and a preinstalled R (32) to generate the
graphics. To validate our analysis software we have tested
another NGS-based HLA-typing data set that was previ-
ously published and that employed randomDNA fragmen-
tation. By analyzing this data set with our tool we could
confirm the previously reported allele calls (33). Our soft-
ware handles unpacked and gzipped FASTQ files. If reads
are provided in other containers, as in the aforementioned
study (33), the user needs to unpack the files before analysis.
Moreover, the FASTQ header has to be taken into account.
The header type is by default set to Casava 1.8, which is the
most recent header format.
RESULTS
In total, 8159 alleles from the IMGT reference database (28)
were considered in our HLA bait panel. The eight loci used
for this design were HLA-A (n = 2019 cDNA sequences),
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Table 1 Benchmark statistics for allele calls that could be achieved in a fully automated manner at three-field resolution (note that some of the reference
samples only had two-field resolution, Supplementary Table S2)
Allele call rate
Locus Genotypes available Different alleles Exact Including alternatives
Mean
alternatives/sample
A 341 114 0.98 0.99 2.21
B 344 122 0.99 1.00 1.03
C 285 53 0.98 0.99 1.58
DRB1 307 80 0.98 0.98 1.08
DQA1 152 20 1.00 1.00 0.06
DQB1 264 18 0.99 0.99 0.06
DPA1 87 5 0.98 0.98 0.00
DPB1 209 40 0.97 0.97 0.57
Columns - Locus: Lists the typed classical gene locus. Genotypes available: Shows the number of samples for which reference genotypes were available.
Only alleles for which a reference call was available were used for calculating the call rate. Different alleles: Lists the number of different alleles within the
reference data set for each locus. The automated calling generates two probable allele calls per diploid sample. Allele calling exact: Shows the validated
allele call rate that was achieved by the automated calling.Allele calling including alternatives: Shows the call rate when including possible alternative alleles
(ambiguities).Mean alternatives/sample: Shows the average number of alternative allele calls (ambiguities) per sample.
HLA-B (n = 2600), HLA-C (n = 1548), HLA-DRB1 (n =
1256), HLA-DQA1 (n = 47), HLA-DQB1 (n = 175), HLA-
DPA1 (n = 34) and HLA-DPB1 (n = 155). The final HLA
bait panel comprised 16,351 distinct RNA baits, each bait
having a length of 120 bp and a cumulative target of 215.5
kb genomic sequence (Supplementary Table S3).
Using the HLA bait panel, we enriched 357 distinct cell
line DNAs that were commercially available and for which
HLA allele data was previously generated using classical
SBT (Supplementary Table S2).
Our fully automated calling algorithm achieved a call rate
of 0.97–1.00 (Table 1,Materials andMethods). Using visual
inspection and manual correction of false calls, the call rate
can be further increased. The concordance between the ref-
erence and the NGS data set was only 80% forHLA-DQA1
(Supplementary Table S2), whileHLA-A showed a concor-
dance of 94% between our results and the available refer-
ence. Querying the read mapping suggested that in most
cases the discordance was due to errors of the reference data
set, i.e. the previous typing methods generated false results
(Figure 2, Supplementary Table S4). For example, HLA-B
of sample IHW09442 has the reference data set genotype
38:01/51:06. Our NGS data in contrast showed that the 3′-
prime part of 38:01 at exon 2 could not be identified in the
NGS data. However, for the genotype HLA-B*38:02/51:06
we could detect reads covering both cDNAs without gaps
(Figure 2). To validate our hypothesis of partially erroneous
reference data, 20 of the discordant samples were selected
and subjected to Luminex-based HLA typing in an accred-
ited routine diagnostics HLA laboratory. These 20 samples
consisted of two batches with 10 samples in each batch.
One batch contained samples with presumably erroneous
reference data. The second batch comprised samples where
we assumed that our method failed to determine the right
genotype (Supplementary Table S5). Seventeen of our 20
assumptions were confirmed. For two additional samples,
reference errors could be identified, although we assumed it
vice versa. For only one sample our assumption was wrong.
It turned out that this error was mainly due to issues in the
IMGT-reference sequence for DRB1*16:05:01. The refer-
ence sequence of DRB1*16:05:01 is incomplete and miss-
Figure 2. Example of an erroneous reference HLA allele. The picture
shows the unique start point coverage (top) and the corresponding short
sequencing reads (bottom) of exon 2 for three different HLA-B alleles of
IHW0994. The red background at the top shows the expected ideal cover-
age for a perfect single start point mapping with 100 bp reads and a mini-
mum truncated mapping length of 70 bp at the exon boundaries. The black
curve shows the sample’s unique start point coverage and the correspond-
ing reads are shown in the lower panel of the figure. The reference geno-
type for HLA-B of this sample is 38:01/51:06 as listed by the commercial
provider. As shown above, the 3’ part of that exon is not equally covered,
thus shows an abnormal read distribution (see purple lines), when consid-
ering 38:01 as a candidate allele. As the only difference between 38:01:01
and 38:02:01 are the nucleotides positioned 32 and 34 bases upstream of
the 3’ end at exon 2, it is highly likely that the reference data set is wrong.
Here we can show that the most probable HLA-B genotype of IHW0994
is 38:02/51:06 or 38:02:01/51:06:01 at the 6-digit level. This was later con-
firmed by Luminex R© HLA typing in another laboratory.
ing parts had been filled with sequence from 16:01:01, thus
the reference allele sequence is a chimeric sequence. Several
such potential chimeric sequences were observed in the ref-
erence data and, thus excluded from further analysis. In the
few other cases (Supplementary Table S2) the discordances
were not due to errors in the reference data set but to low
coverage, resulting in a homozygous call of a heterozygous
sample. A complete list of all calls thatwere not correctly de-
termined in a fully automated manner is provided through
Supplementary Table S6. This table also includes the exam-
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ples where the correct allele was in the list of possible alter-
natives.
To our knowledge, most other HLA genotyping meth-
ods suggest more than two equally likely genotypes per lo-
cus and sample (phase ambiguities). Nevertheless, one allele
combination is normally the most likely genotype, as it usu-
ally is the most common one in the population under study.
However, existing rare alleles are likely alternatives in nearly
every case. The mean of possible alternative alleles in our
benchmark was 0.75 per locus (median: 1, Supplementary
Figure S2).
Using our NGS-based targeted HLA enrichment, geno-
typing yields highly confident HLA calls in a fully auto-
mated manner with only a few ambiguities. We also showed
that data visualization and subsequent visual screening al-
lows for manual correction of possible calling errors and
further increases accuracy. We provide a graphical user in-
terface for our tool to do the automated calling and manual
verification (Figure 1). All analyses can be run on a regular
desktop computer under the most common operating sys-
tems (Linux, Windows and Mac OS (coming soon)).
DISCUSSION
In the present study, we have developed the first reliable
and open access targeted enrichment approach for high-
resolution HLA sequencing, overcoming the limitations
of previous commercial enrichment kits. Instead of PCR-
based enrichment, we decided to use in-solution capture
bait based enrichment that can be performed as an inexpen-
sive single tube reaction. The approach was tested on DNA
from 357 cell lines with high accuracy compared to other
available HLA genotyping approaches.
The method described here consists of two main steps: (i)
targeted in-solution enrichment of the clinically most im-
portant HLA loci and (ii) development of a bioinformatic
tool for complete data analysis fromNGS-derived sequenc-
ing reads to HLA types. Recently, other NGS-based HLA
-typing approaches were reviewed (18). Most of these ap-
proaches rely on NGS of amplicons (20,34). One advantage
using amplicon-based approaches is the high specificity and
the very effective enrichment. However, the possible size
of the amplicon is restricted. In addition, PCR-based tar-
geted enrichment methods often require tedious primer op-
timization steps to avoid co-amplification of pseudogenes
and closely sequence-related HLA loci (e.g. DRB3, DRB4,
DRB5 versus DRB1). Preferential amplification and allelic
dropouts (35,36) are further known problems that can oc-
cur during the locus-specific PCRs. The advantage of the
PCR-free method is the absence of any size limit for the tar-
get region. The HLA bait panel thus comprehensively tar-
gets the complete HLA genes, including flanking sequences,
and may easily be extended by including additional baits
for other specific regions like KIR alleles, SNVs for genetic
blood group/antigen typing or gender-check variants for
Quality Control (QC) purposes, DNA ID tagging Single
Nucleotide Variations (SNVs) and even nonhuman targets
like Cytomegalovirus known as herpesvirus (CMV) might
be added. The HLA panel can also be used as a spike in for
other targeted enrichment designs to ensure confident HLA
calling in parallel. Furthermore, the straightforward sample
handling, which mainly consists of incubation and washing
steps, provides a two-day workflow before the sequencing.
Therefore, our herein described method does not require
obtaining additional instrumentation in most standard se-
quencing laboratories and is amenable to automation and
high-throughput applications. Recently, Major et al. (23)
published a high-throughput HLA genotyping approach
of whole genome data from the 1000 genomes project. Al-
though Major et al. analyzed class I loci only, they demon-
strated that a low sequencing coverage introduces uncer-
tainties to the results. For the low-depthwhole genome data,
the success rate was ∼0.85 at the two-field resolution level.
With our targeted enrichment the achieved unique start
point coverage is greater 50x.
The on-target read mapping rate of our in-solution tar-
geted enrichment is around 5%, when allowing for perfect
matches only. Assuming that our target region reflects only
around 0.007% of the human genome (215.5 kb out of 3.23
Gb for total genome), the target was enriched 700-fold.
With current instruments (Illumina’s HiSeq 2000) we are
able to pool 48 samples in one lane. Increasing the on-target
rate in the future will further increase the possible num-
ber of samples that can be analyzed in parallel. We antic-
ipate that the method will also work with other sequenc-
ing technologies, especially the MiSeq system from Illu-
mina, which showed equally good results in our laboratory
(data not shown, but MiSeq reads are downloadable via
our online repository). Employing theMiSeq, the complete
turnaround time can be further reduced.However, currently
only five samples per MiSeq run are recommended.
Our proposed method is well suited to identify annotated
HLA alleles in large sample sets. A current weakness of our
analysis approach is that the method is not able to identify
novel and not yet annotated alleles in an automated fash-
ion. However, our software tool suggests such potentially
novel alleles to the user. A potential hint to a novel allele
can be a no call for one gene locus while other loci show
clear calls and high coverage, for example. Another scenario
is erroneous homozygous calls where the second not iden-
tified allele is a new allele. In such a case at least one of the
two tables at the right side of the GUI contains alleles that
show a high sequence similarity to the new allele. So if a
homozygous call is identified and diverse alleles (regarding
sequence similarity) are listed at the tables on the right side,
the presence of a new allele is likely. In such instances an-
other independent HLA typing or analysis method of the
same sample is recommended. For this, we would suggest a
conservative mapping and phasing (33) or a de novo assem-
bly approach (37) for which the already obtained data can
be used. Another recommended approach would be a full-
length sequencing approach (14) if available for the given
locus and if an additional DNA sample preparation is ac-
ceptable. Given the ability to detect these instances, and the
comprehensiveness of current allele databases, we consider
the advantages of the approach still too far outweigh these
rare occasions of additional typing efforts.
In summary, we have developed an open-source enrich-
ment kit and comprehensive bioinformatic package for
accurate, high-throughput, high-resolution HLA typing,
effectively by-passing the laborious work step of PCR-
based enrichment prior to NGS. To allow scientists to
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verify their results, we provide a user-friendly graphical
user interface. The current version of the software can
be downloaded at http://www.ikmb.uni-kiel.de/resources/
download-tools/software/hlassign.
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